4-{[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenylamine | 597583-07-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenylamine
• 英文别名: (S)-4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl) aniline；4-(((1-Propyl-1H-imidazol-5-yl)methyl)sulfinyl)aniline；4-[(3-propylimidazol-4-yl)methylsulfinyl]aniline
• CAS: 597583-07-8
• 化学式: C₁₃H₁₇N₃OS
• 分子量: 263.363
• InChiKey: QPYRLSBRGMJDHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  80.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-{[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenylamine 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 15.5h， 生成
  参考文献：
  名称：

  BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST

  摘要：

  公开号：

  EP3567028B1
• 作为产物：
  描述：

  4-氨基苯硫酚 在 双氧水 、 溶剂黄146 、 三乙胺 作用下， 以 水 、 异丙醇 为溶剂， 反应 18.0h， 生成 4-{[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl}phenylamine
  参考文献：
  名称：

  Unusual asymmetric oxidation of sulfide; the diastereoselective oxidation of prochiral sulfide-chiral acid salt with hydrogen peroxide without metal

  摘要：

  The sulfide 4 was treated with chiral acid in a mixture of toluene and methyl iso-butylketone to precipitate the salt, which reacted with 30% H2O2 for 3 weeks at rt. The resulting crystals were collected followed by recrystallization to give the salt of enantiometrically pure sulfoxide and chiral acid 7 in 72% yield and 98.1% de, which was led to chiral sulfoxide S-3 after neutralization. Sulfoxide S-3 was led to S-1a as the candidate for an orally active HIV-1 therapeutic agent. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.03.036

文献信息

• BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1422228A1

  公开（公告）日：2004-05-26

  The present invention provides a novel benzazepine derivative represented by formula : wherein, R1 is a 5- or 6-membered aromatic ring, R2 is lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula -W1-X2-W2- (W1 and W2 are independently S(O)m1 (m1 is 0, 1 or 2), etc., and X2 is an optionally substituted alkylene groupetc. ), a preparation method and use thereof.

  本发明提供了一种新型的苯并氮杂环衍生物，其由以下公式表示： 其中，R1是一个5-或6-成员的芳香环，R2是低级烷基团等，Y是可选地取代的亚氨基，环A和环B是独立地选自一个可选地取代的芳香环，W是公式-W1-X2-W2-（W1和W2是独立地为S(O)m1（m1是0、1或2）等，X2是一个可选地取代的亚烷基团等），其制备方法及其用途。
• ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1593673A1

  公开（公告）日：2005-11-09

  A compound represented by the formula: wherein R1 is a 5- or 6-membered ring; R3 is a hydrogen atom, a lower alkyl group or a lower alkoxy group; R7 and R8 are each a hydrogen atom or a lower alkyl group; Z1 is another 5- or 6-membered aromatic ring; Z2 is a group represented by -Z2a-W1-Z2b- [wherein Z2a and Z2b are each O, S(O)m (wherein m is 0, 1 or 2), an imino group or a bond, and W1 is an alkylene chain]; X is CR (wherein R is a hydrogen atom, a lower alkyl group, a lower alkoxy group, an acyl group, or R and adjacent R4 may form a 5- or 6-membered alicyclic heterocyclic group) or N; R4 is NR5R6 (wherein R5 and R6 are each a hydrogen atom, a hydrocarbon group, a heterocyclic group or an acyl group), or R5 and R6 are bonded to each other to form a heterocyclic group of NR5R6; and R2 is (1) an amino group which may be a quaternary ammonium or oxide, (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or the like; or a salt thereof. The compound has excellent CCR5 antagonistic activity and thus is useful as a prophylactic and/or therapeutic medicine for HIV infection into human peripheral blood monocyte, especially for AIDS.

  一种化合物，其化学式表示为：其中R1是一个5-或6-成员环；R3是氢原子、较低的烷基或较低的烷氧基；R7和R8分别是氢原子或较低的烷基；Z1是另一个5-或6-成员芳香环；Z2是一个由-Z2a-W1-Z2b-表示的基团[其中Z2a和Z2b分别是O、S(O)m（其中m为0、1或2）、亚胺基或键，W1是一个烷基链]；X是CR（其中R是氢原子、较低的烷基、较低的烷氧基、酰基，或R和相邻的R4可能形成5-或6-成员脂环杂环基）或N；R4是NR5R6（其中R5和R6分别是氢原子、烃基、杂环基或酰基），或R5和R6相互连接形成NR5R6的杂环基；R2是（1）可能是季铵盐或氧化物的氨基团，（2）可能包含硫原子或氧原子作为构成环的原子的含氮杂环基，其中氮原子可以转化为季铵盐或氧化物，或类似物；或其盐。该化合物具有出色的CCR5拮抗活性，因此可用作预防和/或治疗HIV感染进入人类外周血单核细胞，特别是艾滋病的药物。
• BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF
  申请人：TOBIRA THERAPEUTICS, INC.

  公开号：US20160008326A1

  公开（公告）日：2016-01-14

  The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R 1 is a 5- to 6-membered ring group which may be substituted; X 1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X 2 is a bivalent group of 1 to 4 atom; Z 1 is a bivalent cyclic ring group or the like; Z 2 is a bond or the like; and R 2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

  本发明提供了一种具有CCR拮抗活性的新环化合物，特别是CCR5拮抗活性，以及其用途。本发明的化合物由以下公式表示：其中，R1是一个可能被取代的5至6成员环基团；X1是键或类似物；环A是一个可能被取代的5至6成员环基团；环B是一个可能被取代的8至10成员环基团；X2是1至4原子的二价基团；Z1是二价环状基团或类似物；Z2是键或类似物；R2是氨基、可能被取代的含氮杂环基团或类似物，或其盐。
• NITROGEN-CONTAINING BENZOHETEROCYCLE COMPOUND COMPRISING CARBOXYLIC ACID GROUP, PREPARATION METHOD AND USE THEREOF
  申请人：Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  公开号：US20200361911A1

  公开（公告）日：2020-11-19

  Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like.

  相关的是一种含氮苯杂环化合物，其通式(I)所示，包含一个羧酸基团，或其立体异构体或药学上可接受的盐。该化合物具有优异的药代动力学性质和极其显著的肝靶向性能，包含该化合物的药物组合物可用作CCR拮抗剂，特别是CCR2和/或CCR5拮抗剂，并可用于介导的疾病，包括但不限于非酒精性脂肪肝病（NAFLD）或类似疾病。
• PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC
  申请人：Tobira Therapeutics, Inc.

  公开号：US20170362207A1

  公开（公告）日：2017-12-21

  The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or salts thereof, high purity intermediates thereto and processes for synthesizing the same.

  该文件涉及高纯度化合物，具有CCR5和/或CCR2拮抗作用，或其盐，以及制备这些化合物的高纯度中间体和合成过程。